奥马利祖马布在慢性诱导性疹 (CIndU) 中是有效和安全的:来自大型多国UCARE研究的现实世界数据
R Soegiharto1, M Alizadeh Aghdam1, J A Sørensen2
1Department of Dermatology/Allergology, University Medical Centre Utrecht, Utrecht, Netherlands.
Allergy
|October 8, 2024
概括
奥马利祖马布 (抗IgE) 对慢性诱导性疹 (CIndU) 非常有效和安全,治疗通常持续超过五年. 这种长时间的持续反映了疾病的慢性性质,而不是治疗失败.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 关于奥马利祖马布在大量慢性诱导性疹病 (CIndU) 群体中的有效性和安全性的长期数据有限.
- 现实世界的证据对于理解CIndU不同患者群体的治疗结果至关重要.
研究的目的:
- 评估奥马利祖马布在大量CIndU患者中的长期有效性和安全性.
- 确定奥马利祖马布治疗持续时间的预测因素,并分析CIndU亚型之间的差异.
主要方法:
- 一项跨国多中心研究包括2009年至2022年用奥马利祖马布治疗的CIndU患者.
- 使用Kaplan-Meier生存和回归分析来评估治疗持续时间和结果.
主要成果:
- 奥马利祖马布在234名CIndU患者中显示出高效率 (73%完整/良好反应) 和安全性.
- 平均治疗持续时间超过5年,疾病控制是继续治疗的主要原因.
- 在CIndU亚型之间没有观察到响应或停药的显著差异.
结论:
- 奥马利祖马布是所有CIndU亚型的高效和安全的治疗选择.
- 长时间的治疗时间突出了CIndU的慢性性质,并支持奥马利祖马布的持续临床效用.
- 这些发现支持奥马利祖马布在临床上广泛用于管理CIndU.
更多相关视频
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
241
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
241
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
226
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
226
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97


